The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cedro-Tanda Alberto, Gómez-Romero Laura, Alcaraz Nicolás, de Anda-Jauregui Guillermo, Peñaloza Fernando, Moreno Bernardo, Escobar-Arrazola Marco A, Ramirez-Vega Oscar A, Munguia-Garza Paulina, Garcia-Cardenas Francisco, Cisneros-Villanueva Mireya, Moreno-Camacho Jose L, Rodriguez-Gallegos Jorge, Luna-Ruiz Esparza Marco A, Fernández Rojas Miguel A, Mendoza-Vargas Alfredo, Reyes-Grajeda Juan Pablo, Campos-Romero Abraham, Angulo Ofelia, Ruiz Rosaura, Sheinbaum-Pardo Claudia, Sifuentes-Osornio José, Kershenobich David, Hidalgo-Miranda Alfredo, Herrera Luis A
Аннотация
The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We reported the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. We reported the effective reproduction number (Rt) of B.1.1.519 and presented evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519. The B.1.1.519 variant was predominant between November 2020 and May 2021, reaching 90% of all cases sequenced in February 2021. It is characterized by three amino acid changes in the spike protein: T478K, P681H, and T732A. Its Rt varies between 0.5 and 2.9. Its geographical origin remain to be investigated. Patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (p = 0.000296, 1.33-2.6 95% CI) and a 2.35-fold increase for hospitalization (p = 0.005, 1.32-4.34 95% CI). The continuous monitoring of this and other variants will be required to control the ongoing pandemic as it evolves.